Podanie dożylne immunoglobuliny (IVIG) może poprawić objawy neuropatii u chorych z okresem poboreliozowym - stwierdzili naukowcy naukowcy w dniu 28 kwietnia- 2009 w American Academy of Neurology (AAN)
https://www.researchednutritionals.com/library/lyme/immunoglobulin-therapy-for-lyme/
--------------------------------------------------
Dr Jones:
Jeśli same antybiotyki nie pomagają to można dodać IV immunoglobuliny (Ig iv), może to doprowadzić do wyleczenia. IVIG jest bardzo dobry/pomocny , ale również bardzo kosztowny.
http://lymeconnection.org/news_publications/meet_the_lyme_disease_experts.html/title/straight-talk-with-pediatrician-dr-charles-ray-jones
------------------------------------------------
May 2, 2009 Intravenous immunoglobulin (IVIG) therapy may improve neuropathic symptoms in patients with post-treatment Lyme syndrome, researchers stated here on April 28 at the American Academy of Neurology (AAN) 61st Annual Meeting.
A significant number of patients who had Lyme disease will continue to have lingering symptoms referred to as post-treatment Lyme syndrome, according to presenter Amiram Katz, MD, Lambert Professional Center, Orange, Connecticut. Similar symptoms are seen in patients who have received the Lymerix vaccine.
The study included 30 patients seen by Dr. Katz (13 females, 17 males; mean age 48.2 years) who complained of neuropathic pain.
Of the patients, 22 had a history of Lyme disease and 8 patients had received the Lymerix vaccine.
All patients had antibodies to outer surface protein A (anti-OspA) and persistent symptoms despite at least 1 course of antibiotics.
Twenty-four patients had electrodiagnostic studies, but there was a poor correlation between electrodiagnostic and nerve biopsy results.
Four patients with abnormal electrodiagnostic studies had normal epidermal nerve fibre density on nerve biopsy, while 10 patients with normal electrodiagnostic studies had abnormal epidermal nerve fibre density on nerve biopsy. Three patients had inflammatory changes around the nerve endings on skin biopsy.
All patients were treated with IVIG 2 g/kg per month for at least 6 months.
After IVIG treatment, all patients had improvement of their neurological examination with respect to their sensation, Achilles reflex, and Romberg test. Several patients also showed improvement in the number of nerve fibres on repeat nerve biopsy after treatment. There was no placebo group.
“The diagnosis of chronic Lyme disease is not widely accepted, yet these patients have symptoms and nerve biopsies that respond to IVIG treatment, legitimising their complaints,” concluded Dr. Katz.
[Presentation title: Diminished Epidermal Nerve Fiber Density in Patients With Antibodies to Outer Surface Protein A (OspA) of B. burgdorferi Improves with Intravenous Immunoglobulin Therapy. Abstract P02.021]
Source: docguide.com by Andrew Wilner, MD
https://www.researchednutritionals.com/library/lyme/immunoglobulin-therapy-for-lyme/
-----------------------------------------------
,,If the patient complains of tingling, numbness and burning sensations (suggestive of neuropathy), I then would check for vitamin deficiencies (B12, folic acid), heavy metal toxicity (mercury, lead, arsenic), thyroid and hormonal disorders, immune deficiency, as well as checking for autoimmune markers (anti-ganglioside antibodies) against the nerves. These antibodies are seen in patients with autoimmune disorders with demyelination, and also in POTS/dysautonomia, implying the need for immune support, with treatment like IVIG (IV immunoglobulin therapy).,,
http://lymeconnection.org/news_publications/meet_the_lyme_disease_experts.html/title/dr-richard-horowitz
-----------------------------------------------
.....,, Therefore, to address these issues, my Lyme literate neurologist began me on an IV treatment known as IVIG. To put it simply, the IV’s consisted of purified blood plasma, of which was used to help support, and thus restore my nerves in a way that my body otherwise could not do at its own due to the degree of damage that had already taken place. The IV’s came once a week, and took about 5-6 hours. The drip had to go very slow, as adverse side effects were common, and I personally would experience screaming migraines and increased lethargy afterwards. My white blood cell count would also dip very low, therefore causing the infusions to be taken treatment by treatment, as if they did not return to the normal range, I could not receive my IV. According to Amiram Katz, the doctor who administered my IV’s, IVIG “may be the only safe immune-modulating treatment in the presence of infection,” and though it “has worked with 5,000 patients with Lyme disease,” it is typically “given for complications of Lyme and not for Lyme itself.” Much like most all treatments for chronic Lyme, one undoubtedly feels worse before they begin to see any improvement. Moving one step forward and two steps back is the name of the game, and I truly cannot say I ever felt “good” when getting IVIG. Overall, I did the treatments for 2, six month intervals, with a nurse coming to the house to administer my IV’s once a week. ....,,
http://www.beyondthebite4life.com/2015/06/hope-for-healing-ivig-and-chronic-lyme-disease.html
-----------------------------------------
Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases
,, Significant improvements have occurred in the treatment of PIDD with antibody deficiency in the past 60 years since the first patients were treated with IG therapy. Treatment with IVIG significantly decreased mortality and morbidity and increased life expectancy, as patients had increased serum IgG levels and fewer serious bacterial infections. SCIG therapy confers several additional benefits for PIDD patients including: maintenance of serum IgG levels in the physiologic range with “steady state” kinetics, reduction in the rate of infections, lower rates of systemic adverse effects, and important benefits for the patient’s QOL. PIDD patients have a number of choices for their IG treatment regimen. This allows the practitioner to tailor therapy to fit an individual’s medical condition, lifestyle. The development of new SCIG products that facilitate the administration of larger volumes of IG delivered subcutaneously will offer additional options for long term IgG replacement therapy.,,
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3430092/
------------------------------------------------
Clinical applications of intravenous immunoglobulins in neurology
Intravenous immunoglobulin (IVIg) is used increasingly in the management of patients with neurological conditions. The efficacy and safety of IVIg treatment in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and Guillain–Barré syndrome (GBS) have been established clearly in randomized controlled trials and summarized in Cochrane systematic reviews. However, questions remain regarding the dose, timing and duration of IVIg treatment in both disorders. Reports about successful IVIg treatment in other neurological conditions exist, but its use remains investigational. IVIg has been shown to be efficacious as second-line therapy in patients with dermatomyositis and suggested to be of benefit in some patients with polymyositis. In patients with inclusion body myositis, IVIg was not shown to be effective. IVIg is also a treatment option in exacerbations of myasthenia gravis. Studies with IVIg in patients with Alzheimer's disease have reported increased plasma anti-Aβ antibody titres associated with decreased Aβ peptide levels in the cerebrospinal fluid following IVIg treatment. These changes at the molecular level were accompanied by improved cognitive function, and large-scale randomized trials are under way.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2801030/
---------------------------------
Lyme radiculoneuritis treated with intravenous immunoglobulin
http://www.neurology.org/content/46/4/1174.short
--------------------------------
,,..........i’m in a presentation, by dr. amiram katz, neurologist and assistant professor of neurology at yale university, called “IVIg treatment for autoimmune issues in lyme disease: II. neurodegenerative and other neuro inflammatory conditions.” my attention span is powering down, largely because the cost of IVIg (intravenous immunoglobulin) treatment is so astronomical that many insurance companies will not cover its use. in the lyme world, it is typically administered under the care of a neurologist or neurosurgeon. this posting does not cover the myriad of potential uses for IVIg therapy. if you’re interested in reading more about how it’s being used through different medical channels, what i’m writing here is pretty limited to what i’ve heard at this conference and have a very small knowledge base of IVIg therapies beyond that. this is the second or third lecture i’ve been to where IVIg is the heart of the research, but i’ve heard it mentioned in many of the presentations. tidbits from those other lectures will no doubt be included. please feel free to comment on it if you feel you have information relevant to neuro-lyme or neuro-inflammatory conditions.
so what is intravenous immunoglobulin? according to BDI Pharma, a pharmaceutical distributor who provides this blood byproduct, IVIg is:
a sterile solution of concentrated antibodies extracted from healthy donors which is administered into a vein. IVIG is used to treat disorders of the immune system or to boost immune response to serious illness, and to treat immuno-suppressed recipients of bone marrow transplants. Antibodies are responsible for defending our bodies from pathogens, such as viruses and bacteria.according to dr. katz, it takes 50,000 donors to create a viable product. this is done through a very extensive process of refining and cleaning, washing the blood. he states that about 10% of 5,000 patients required IVIg therapies. it has been preliminarily successful in treating complications of lyme, but not lyme disease itself. it should not be used as a treatment for lyme and as such, lyme protocols should still be followed. in cases where the patient has severe neurological symptoms and has undergone typical treatment avenues with marginal or minimal success, this patient could be a good candidate for IVIg. interestingly, dr. katz believes that chronic lyme disease is actually an autoimmune disease, which is something that my lyme literate rheumatologist has also stated. the majority of long term damage is caused by autoimmunity and inflammation, a theme throughout this conference and the lyme world.
how exactly IVIg works in the body is still unclear, though it does seem to temporarily create necessary antibodies in patients who are unable to produce them on their own (immunodeficient). IVIg can also be beneficial for patients with autoimmune diseases, conditions where the body has an excess of antibodies and subsequently, they turn on the body and attack the patient. IVIg seems to regulate the immune system in most cases.
IVIg can be used to treat an incredible array for diseases and has been particularly effective in cases with patients who have MS. over a ten-year period, dr. katz used IVIg therapy for patients with ALS. only two of twenty patients who received this therapy and improved. there was still a fatal outcome, but their life-span was extended by a couple of years. dr. madeline cunningham, in another presentation at the ilads conference, relayed that in pediatric cases of PANDAS (pediatric autoimmune neuropsychiatric disorders), after one month, patients greatly improved with IVIg treatment. OCD and tics were greatly lessened, if even present, after 3-6 months of treatment.
in the case of late manifestations of lyme disease, autonomic neuropathy is common. according to the mayo clinic, autonomic neuropathy can be described as “a nerve disorder that affects involuntary body functions, including heart rate, blood pressure, perspiration and digestion.” until now, autonomic dysfunction was measured by unreliable, costly and tedious testing. dr. katz, by counting sweat gland nerve fiber density, has been able to more easily diagnose autonomic neuropathy. his research is demonstrating the ability of IVIg therapy to repair autonomic neuropathy, which “and this repair might sometimes antedate recovery of small fiber neuropathy.”
due to the cost prohibitive nature of IVIg therapies and the fact that, for many diseases and conditions, it’s still in the experimental stages, most patients will not be good candidates for this type of treatment. however, those who have exhausted traditional, as well as more aggressive therapies, and are still suffering from severe symptoms, might consider consulting with a neurologist who is familiar with IVIg. who knows? maybe your insurance will cover it!........,,
https://lymeinthecoconut.wordpress.com/tag/ivig-treatment-for-chronic-lyme-disease/
-----------------------------------
Ulotka Flebogamma iv pasteryzowany roztwór
Spis treści ulotki:
Co to jest FLEBOGAMMA IV pasteryzowany roztwór i w jakim celu się go stosuje2. Zanim zastosuje się FLEBOGAMMA IVpasteryzowany roztwór
3. Jak stosować FLEBOGAMMA IVpasteryzowany roztwór
4. Możliwe działania niepożądane
5. Przechowywanie FLEBOGAMMA IVpasteryzowany roztwór
6. Inne konieczne informacje dotyczące FLEBOGAMMA IVpasteryzowany roztwór
Co to jest FLEBOGAMMA IVpasteryzowany roztwór i w jakim celu się go stosuje
FLEBOGAMMA IV pasteryzowany roztwór to roztwór do infuzji dożylnych zawierający g/1 immunoglobuliny ludzkiej normalnej.
Produkt leczniczy należy do grupy terapeutycznej leków zwanych surowicami i immunoglobulinami.
Flebogamma IV pasteryzowany roztwór stosuje się w:
Leczenie substytucyjne
Pierwotne niedobory immunologiczne:
- wrodzona agammaglobulinemia i hipogammaglobulinemia
- pospolity zmienny niedobór odporności
- ciężkie złożone niedobory odporności
- zespół Wiscott Aldrich’a
Szpiczak mnogi lub przewlekła białaczka limfatyczna z ciężką wtórną hipogammaglobulinemią i nawracającymi zakażeniami.
W leczeniu nawracających zakażeń u dzieci z wrodzonym AIDS.
Leczenie immunomoduluiace
- Samoistna plamica małopłytkowa (ITP) u dzieci i dorosłych o dużym ryzyku krwawienia lub przed zabiegiem operacyjnym, kiedy niezbędny jest szybki wzrost ilości płytek.
- Zespół Guillain-Barre.
- Choroba Kawasaki
Allogeniczne przeszczepianie szpiku kostnego
2. Zanim zastosuje się FLEBOGAMMA IVpasteryzowany roztwór
https://imeds.pl/flebogamma-iv-pasteryzowany-roztwor-50-mg-ml-5-0-5-g-10-ml-2-5-g-50-ml-5-g-100-ml-10-g-200-ml
----------------------------------------
Brak komentarzy:
Prześlij komentarz